The Market For Cell Therapy Manufacturing - Strategies for Pricing, Cost Control, Reimbursement, and Distribution
Traditionally, one of the major issues with commercializing cell therapy products has been manufacturing bottlenecks. The heterogeneous nature of cell therapy products has introduced manufacturing complexity and regulatory concerns, as well as scale-up complexities that are not present within traditional pharmaceutical manufacturing. Furthermore, much of cell therapy manufacturing now involves patient-specific cell therapies, where cells for an individual patient are processed one batch at a time.
While many factors contribute to high pricing associated with cell therapies, a critical factor affecting the pricing of a cell therapy product is the cost of continuously manufacturing the product. To keep a cell therapy product “on market,” manufacturing costs of must be covered and a profit margin achieved. Therefore, great consideration must be given to the variables affecting the costs of goods (COGs) associated with cell therapy manufacturing, as well as strategies for process optimization.
Currently, allogeneic cell therapy manufacturing dominates over autologous cell therapy manufacturing, although clinical data in support of patient-specific therapy is compelling. There are opportunities for the development of both autologous and allogeneic cell therapies, which vary greatly in their manufacturing requirements, routes for patient administration, and cost structures.
Among cell therapy companies, the pressure for manufacturing process innovation can incentivize them to seek third-party partners who possess technical, manufacturing, and regulatory expertise in cell therapy development and manufacturing, such as cell therapy contract and development manufacturing organizations (CDMOs). Currently, there are more than 20 cell therapy CDMO’s specializing in manufacturing and clinical trial support for cell therapy companies, including WuXi PharmaTech (and its subsidiary WuXi AppTec), Lonza Group, PCT (a Caladrius company), MEDINET, Cell and Gene Therapy Catapult, Brammer Bio, KBI Biopharmaceuticals, PharmaCell, Roslin Cell Therapies, apceth Biopharma, and more.
Benefits of partnering with a cell therapy CDMO include scalability, speed to market, access to technical expertise without overhead costs, and cost efficiencies. This report considers the role of cell therapy CDMOs, as well as the importance of in-house manufacturing at cell therapy companies worldwide.
This global strategic report provides detailed analysis of ten leading cell therapy companies worldwide, evaluating the strengths of each company, as well as identifying cell therapy products in development, manufacturing strategies, and partnerships. These companies include:
Additionally, the report identifies cell therapy products that have been reviewed and approved by internationally-recognized regulatory agencies, as well as products brought to market in the U.S. with FDA approval. It also specifies which cell therapies have since been pulled from market, due to factors such as low adoption rates, unsuccessful reimbursement strategies, or high cost of manufacturing.
The report analyzes time frames for cell therapy product development, distribution channels, key trends and technologies impacting cell therapy manufacturing, cost control measures, and challenges and considerations affecting with cell therapy manufacturing.
It provides an overview of the regulatory environment affecting cell therapy manufacturing in key countries worldwide, evaluating the importance of the recent FDA guidelines for Human Cell and Tissue-based Products (HCT/Ps) and the 21st Century Cures Act, as well as accelerated pathways for cell therapy approvals in Japan, including the:
Act on the Safety of Regenerative Medicine (Law No. 85/2013)
Pharmaceuticals and Medical Device (PMD) Act (Law No. 84/2013)
Based in Washington, DC, BioInformant is first and only market research firm to specialize in the stem cell industry. Unlike other publishers that hire analysts from foreign countries, BioInformant is an American-based company with more than 10 years of experience with tracking the cell therapy market (2006 to present). BioInformant compiled this global strategic report using primary interviews with more than 50 participants from across the cell therapy manufacturing industry, including representatives from:
Gamida Cell (Dr. Yael Margolin)
Pluristem (Yaky Yanay)
Cynata Therapeutics (Dr. Paul Wotton)
Accellta (Dr. Itzchak Angel and Eran Cohen)
Stem Cell Medicine Ltd. (Dr. Frida Grynspan)
Minerva Biotechnologies (Dr. Cynthia Bamdad)
RoosterBio (Dr. Jon Rowley)
Universal Cells (Gregory Block)
It also incorporates secondary findings from SEC filings, company websites, press releases, investor presentations, and government policy documents (FDA / PMDA). Produced for companies involved with cell therapy product development, this global strategic report offers critical insights into strategies for optimizing modern cell therapy manufacturing.
Astellas Pharma, and Subsidiary Ocata Therapeutics
Gamida Cell Ltd.
Organogenesis, Inc. & Novartis AG
Advanced Tissue Sciences
JCR Pharmaceuticals Co. Ltd. (Licensee of Mesoblast Ltd.)
MasTHerCell, Acquired by Orgenesis
PCT, a Caladrius Company (Previously Neostem)
WuXi PharmaTech, Including Subsidiary WuXi AppTech, Inc.
Cell and Gene Therapy Catapult
KBI Biopharma (Acquired Opexa Assets, February 2017)
Brammer Bio (Formed through Merger of Brammer Biopharmaceuticals and Florida Biologix)
Roslin Cell Therapies, a Subsidiary of Roslin Cells
Cognate Bioservices, Inc.
MEDINET Co. Ltd.
The Clinical Trial Company (TCTC)
Miltenyi Bioprocess, the Contract Manufacturing Business of Miltenyi Biotec
Lonza Group, Cell Therapy Manufacturing Unit
Cellular Therapeutics Ltd. (CTL)
CTI Clinical Trial and Consulting